Buprenorphine, Pancreatic Cancer, and a Hydromorphone PCA

Do not stop it abruptly. The fellow's premise is partly right - buprenorphine's high affinity and partial agonism blunt full-agonist effect - but the conclusion is wrong. Abrupt discontinuation risks withdrawal, relapse, and the loss of the therapeutic relationship at the worst possible moment, and it solves the wrong problem.

What actually went wrong: the PCA is inadequate by design. Basal rate zero, 0.2 mg boluses, and 1 mg demand doses are mismatched and far too small for severe pancreatic pain in a patient already opioid tolerant.

A workable plan:

• Continue buprenorphine and split the dose - 4 mg four times daily, or 2 mg every 6 hours - which provides more stable receptor coverage and often restores analgesia.
• Increase the total daily dose toward 20–24 mg if needed.
• Add a full agonist at adequate doses, titrated to effect, with the PCA reassessed hourly at first. Higher doses can overcome partial agonism; titration is simply less predictable.
• Because creatinine is 2.4, switch from hydromorphone to fentanyl, which has no active renally cleared metabolites.
• Treat the cancer pain properly: a celiac plexus block or neurolysis is highly effective for pancreatic pain, and dexamethasone, gabapentinoids for the neuropathic component, and ketamine all have a role.

If she genuinely needs very high full-agonist doses, a planned transition to methadone with addiction medicine input is a legitimate option - but as a deliberate, coordinated step, not a reflexive stop. Involve addiction medicine and continue her buprenorphine prescriber relationship throughout.

This is not simply 'too much opioid.' The combination of sedation, myoclonus, escalating pain despite opioids, and renal failure points to opioid-induced neurotoxicity: hydromorphone's renally cleared metabolites accumulate, producing hyperalgesia, myoclonus, and delirium. The high pain score alongside sedation is the signature.

Differential to clear: hepatic encephalopathy (AST 180), hypercalcemia, sepsis, dehydration and AKI, brain metastases, urinary retention or constipation, and a delirium from any of these. Check calcium, ammonia, glucose, electrolytes, and a full medication review.

Management:

• Do not give naloxone for sedation alone. Reserve reversal for clinically significant respiratory depression with hypoxia, and then titrate small aliquots (0.04–0.08 mg IV), never a full ampule - complete reversal in a physically dependent patient precipitates pain crisis, withdrawal, and catecholamine surge.
• Rotate to fentanyl, reducing or stopping hydromorphone.
• Hydrate, correct electrolytes, treat constipation aggressively with a scheduled bowel regimen, and continue monitoring.
• Set objective monitoring: sedation scale and respiratory rate every 1–2 hours, consider capnography, and give nursing explicit call parameters.

Then step back. Her prognosis is short. The questions that matter are whether she is comfortable, whether she can interact with her son, and what she wants. Open the goals-of-care conversation, document a health care agent, and make sure analgesia decisions are made in the service of her stated goals rather than around a number on a pain scale.

Addiction care is not a separate track from cancer care. Continue buprenorphine through admission, discharge, and hospice. Hospital systems and hospices sometimes refuse to continue buprenorphine or methadone - advocate, name the consequence (withdrawal, relapse, uncontrolled pain), and get pharmacy and the medical director involved if needed. Involve her outpatient prescriber and addiction medicine. Scrub stigmatizing language from the chart; 'drug-seeking' in the record will distort every subsequent decision.

Goals of care: arrange an early palliative care consultation - in metastatic pancreatic cancer this improves quality of life and, in trials, survival. Clarify what she understands about prognosis, what matters most (time at home, lucidity with her son, pain control), her health care agent, and code status. Document it. Screen for depression and existential distress, and treat cautiously with her renal and hepatic function in mind - low-dose mirtazapine for appetite and sleep is often a better fit than an SSRI with hyponatremia risk; assess suicide risk directly.

Her son: this is a clinical issue, not a social afterthought. Involve social work and, if available, a child and family support service; evidence-based programs for children of a parent with advanced cancer reduce distress. Help her plan who will care for him, what she wants him to know, and whether she wants to record letters or messages. Ask about guardianship and financial planning - these are the concrete things she is likely lying awake about.

Articulate the value of all this plainly: honoring her recovery, controlling her pain, and supporting her son are not competing priorities; they are the same priority - the quality of the time she has left.